Other Grants & Awards Programs
-
2021 AVF-JOBST Research Grant
The American Venous Forum (AVF) and the American Venous Forum Foundation (AVFF) seek to advance knowledge, excellence, and innovation in venous and lymphatic health through education, research, and public advocacy. In 1995, the AVF, in collaboration with JOBST, initiated the JOBST Research Grant in Venous and Lymphatic Diseases. For more than 20 years, the research developed by grant recipients has helped advance the understanding and treatment of venous and lymphatic diseases.
The AVF Foundation is proud to announce that they are now accepting submissions for the 2021 AVF-JOBST Research Grant which will provide a $90,000 grant over two years for original, basic or clinical research in venous or lymphatic disease. The competition is open to residents and fellows in a vascular training program, as well as physicians who have completed their training within the past five (5) years. Applicants are AVF members and based within the United States.
Areas of emphasis:
-The science of compression therapy for chronic venous insufficiency.
-Treatment for venous ulceration.
-Pathophysiology of venous ulceration.
-Diagnosis of lymphatic diseases.
-The science of management of lymphatic disease.
-Diagnosis and management of iliac vein compression.
-Physiopathology of deep venous thrombosisDeadline: Monday, October 12 at 5:00pm ET
Learn More > -
Elimination of lymphatic filariasis and elimination and control of other NTDs
Globally, neglected tropical diseases (NTDs) affect more than one billion people, primarily in the world’s poorest nations. CDC, together with other U.S. government and global partners, is supporting elimination/control of six NTDs (lymphatic filariasis, onchocerciasis, trachoma, soil-transmitted helminths, schistosomiasis, Guinea worm) through community mass drug administration (MDA), water filters, or other tool-ready public health interventions such as vector control or improved water, sanitation and hygiene (WASH). Among these, lymphatic filariasis (LF), a mosquito-borne disease that can lead to permanent disability from elephantiasis or hydrocele, was targeted for elimination by 2020. Although the global target was not met, 16 countries have eliminated LF as a public health problem, and many others are close to achieving elimination. Achieving global targets is challenging in many settings, such as highly urban areas. Control of LF usually depends on provision of antiparasitic drugs through MDA with high (>65%) community coverage for at least five years in order break the cycle of transmission. Locally relevant strategies ensuring sufficiently high MDA community coverage and low levels of systematic non-compliance are needed. New data support that addition of a third drug, ivermectin, in some settings to the traditional dual drug (dethylcarbamazine [DEC] plus albendazole) regimen can shorten the number of annual MDAs required for LF elimination if high community MDA coverage is achieved. After reaching MDA targets, country programs must develop feasible and sustainable surveillance systems able to identify LF recrudescence, as well as processes that effectively manage areas of persistent transmission in order to limit LF spread. Other NTDs have potential to be eradicated (Guinea worm), eliminated (onchocerciasis, trachoma) or controlled (schistosomiasis, soil transmitted helminths) through well-conducted quality community campaigns over a sustained period.
The Division of Parasitic Diseases and Malaria (DPDM) at the Centers for Disease Control and Prevention (CDC) has provided technical assistance on NTD elimination/control for national programs in Africa, the Americas, Asia and the Pacific over many decades, working closely with the World Health Organization (WHO) and national health ministries.
The purpose of this announcement is to support endemic countries in strengthening their program capacity for elimination/control of LF and other NTDs through achieving MDA coverage targets; establishing ongoing, systematic surveillance systems that can identify recrudescence of infection; establishing standard procedures for responding promptly to persistent or recrudescent transmission; and supporting integrated health services for LF and other NTDs within national health systems. For LF, measurable outcomes of the program will be: improved quality of, access to, and participation in MDA campaigns; better understanding of community participation (and non-participation) in MDAs by countries and other stakeholders; improved management of chronic disease in communities; identification of appropriate MDA stopping points and hotspot management; and establishment of feasible yet high-quality monitoring, evaluation and surveillance before, during and after MDAs. For other NTDs, measurable outcomes will be improved quality of MDAs; understanding of MDA starting and stopping points (e.g., onchocerciasis); high quality conduct of NTD monitoring, evaluation and surveillance, including post-elimination surveillance; and integration of NTD surveillance and services within existing health systems.
This announcement is only for non-research activities supported by CDC. If research is proposed, the application will not be reviewed. For the definition of research, please see the CDC Web site at the following Internet address: http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf.
Opportunity Number: CDC-RFA-GH21-2104
Learn More >
Forecasted Date: Jun 16, 2020
Last Updated Date: Jun 16, 2020
Estimated Post Date: Aug 11, 2020
Estimated Application Due Date: Oct 10, 2020 Electronically submitted applications must be submitted no later than 11:59 p.m., ET, on the listed application due date.
Estimated Award Date: Apr 15, 2021
Estimated Project Start Date: Apr 15, 2021 -
Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a., Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model systems of the human BBB to complement research currently based on animal models.
For application instructions and more information, please visit https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-021.html.
Open Date (Earliest Submission Date): September 17, 2019
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date(s): December 2, 2019, October 19, 2020; All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More > -
Patient-Centered Outcomes Research Institute
PCORI funds research into conditions that affect large numbers of people across a range of populations; conditions that place a heavy burden on individuals, families, specific populations, and society; and rare diseases, which are difficult to study. PCORI funds research through organizations and not individuals.
PCORI funds research that offers patients and caregivers the information they need to make important healthcare decisions. Our scientific research portfolio is divided among two programs, which together reflect our National Priorities for Research. Each program leads the development of PCORI Funding Announcements that may be either broad calls for applications or targeted to specific topics. These programs also participate in the selection of awards and oversee the projects as they progress.
In addition, the Evaluation and Analysis program provides evaluation expertise, while the Engagement program gives patients, caregivers, clinicians, and other healthcare stakeholders opportunities for meaningful involvement in all our activities.
Learn More > -
Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)
The purpose of this FOA (#RFA-HL-20-014) is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questions; or for broader implementation of guidelines for managing these diseases.
This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patient-reported outcomes with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations.
This initiative will allow applicants to study rare or related rare diseases, disorders, conditions or syndromes together based on pathogenesis, affected biochemical, cellular or physiological features or organ system involvement. Studying related rare diseases within the same cohort could help understand the nuances, and knowledge gained from one disease could accelerate the advances in related diseases. For example, investigators may propose to study hemoglobin disorders rather than only sickle cell anemia or thalassemia.
For application instructions and more information, please visit https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-20-014.html.
Open Date (Earliest Submission Date): May 18, 2019
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date(s): June 18, 2019, June 17, 2020 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More > -
DOD’s Congressionally Directed Medical Research Programs (CDMRP) - BCRP Pre-Announcements
Last year researchers looking at the intersection of lymphedema and breast cancer were encouraged to compete for funding opportunities through the CDMRP’s Breast Cancer Research Program (BCRP). Please see the information below in this regard.
The Fiscal Year 2019 (FY19) Defense Appropriation Act provides funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP). Recently released pre-announcements may be found at http://cdmrp.army.mil/pubs/press/press to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.
FY19 funding opportunities are anticipated to be released in January 2019 for the following programs:
Breast Cancer Research Program
Ovarian Cancer Research Program
Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement. FY19 pre-announcements can be found in the CDMRP home page features at http://cdmrp.army.mil.
Researchers investigating the intersection of lymphedema and breast cancer may be interested in the following grant opportunities recently released.
DOD
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Innovator Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312196
DOD
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Breakthrough Fellowship Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312197
DOD
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Breakthrough Award Level 4 Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312198
DOD
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Era of Hope Scholar Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312195
DOD
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Distinguished Investigator Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312176DOD
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Breakthrough Award Levels 1 and 2
Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312177DOD
Learn More >
Department of Defense
Dept. of the Army—USAMRAA
DoD Breast Cancer, Breakthrough Award Level 3 Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312178 -
DOD’s Congressionally Directed Medical Research Programs (CDMRP) - PRMRP Grant Opportunities
Peer Reviewed Medical Research Program (PRMRP) Grant Opportunities. – PRMRP funds medical research for a list of conditions and diseases that have been identified by Congress as disproportionately affecting military personnel. LE&RN will be working over the course of this year to include “lymphatic diseases” to this list.
This year’s PRMRP includes “burn pit exposures” and “vascular malformations.” Any researchers looking at this connection between burn pit exposures and the onset of lymphedema should look at the opportunities below. Researchers who are working on research involving vascular or lymphatic malformations may also find funding through these opportunities. Researchers are also encouraged to apply for funding through the designation of vascular malformations as this may encompass vascular anomalies of only veins, only lymph vessels, both veins and lymph vessels, or both arteries and veins.
(https://www.hopkinsmedicine.org/interventional-radiology/conditions/malformations/index.html)LE&RN is working to include “lymphatic diseases” as eligible for study through the fiscal year (FY) 2020 PRMRP and this will definitely improve the ability of researchers to compete successfully for this funding, but the categories above should be seen as an opportunity for researchers to get their foot in the PRMRP’s door.
DOD
Department of Defense
Dept. of the Army—USAMRAA
CDMRP PRMRP Investigator-Initiated Research Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312036
DOD
Department of Defense
Dept. of the Army—USAMRAA
CDMRP PRMRP Technology/Therapeutic Development Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312037
DOD
Learn More >
Department of Defense
Dept. of the Army—USAMRAA
CDMRP PRMRP Discovery Award
Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312033
DOD
Department of Defense
Dept. of the Army—USAMRAA
CDMRP PRMRP Clinical Trial Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312034
DOD
Department of Defense
Dept. of the Army—USAMRAA
CDMRP PRMRP Focused Program Award Synopsis 1
https://www.grants.gov/web/grants/view-opportunity.html?oppId=312035 -
Lymphatics in Health and Disease in the Digestive System (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.
NIDDK intends to commit $1,000,000 in FY 2018 to fund up to 3 R01 awards. Application budgets are limited to $250,000 direct costs per year exclusive of subcontracts F&A. The maximum project period is 5 years.
For application instructions and more information, please visit https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-021.html.
Open Date (Earliest Submission Date) - January 21, 2019
Letter of Intent Due Date(s) - January 21, 2019
Application Due Date(s) - February 21, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More > -
Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (R21-Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Purpose: Attaining effective therapies for rare diseases is challenging due to their low prevalence resulting in fewer patients, clinicians, researchers, and resources compared to common diseases. This leads to gaps in our understanding of a rare disease’s natural history, and a dearth of suitable biomarkers or clinical outcome measures, or of other components needed to design, conduct, and interpret rigorous clinical trials.
The Office of Rare Diseases Research (ORDR) within the National Center for Advancing Translational Sciences (NCATS) along with the Institutes and Centers (ICs) listed in Part I at the National Institutes of Health (NIH) intend to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
For application instructions and more information, please visit https://grants.nih.gov/grants/guide/pa-files/PAR-18-953.html.
Open Date (Earliest Submission Date) - December 07, 2018
Letter of Intent Due Date(s) - 30 days prior to receipt date
Application Due Date(s) - January 7, 2019, June 10, 2019, October 24, 2019, June 8, 2020, October 26, 2020, June 7, 2021, October 25, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More > -
Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (R03-Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
Purpose: Attaining effective therapies for rare diseases is challenging due to their low prevalence resulting in fewer patients, clinicians, researchers, and resources compared to common diseases. This leads to gaps in our understanding of a rare disease’s natural history, and a dearth of suitable biomarkers or clinical outcome measures, or of other components needed to design, conduct, and interpret rigorous clinical trials.
The Office of Rare Diseases Research (ORDR) within the National Center for Advancing Translational Sciences (NCATS) along with the Institutes and Centers (ICs) listed in Part I at the National Institutes of Health (NIH) intend to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
For application instructions and more information, please visit https://grants.nih.gov/grants/guide/pa-files/PAR-18-952.html.
Open Date (Earliest Submission Date) - December 07, 2018
Letter of Intent Due Date(s) - 30 days prior to the application due date
Application Due Date(s) - January 7, 2019, June 10, 2019, October 24, 2019, June 8, 2020, October 26, 2020, June 7, 2021, October 25, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Learn More > - 12